M5281635
Relugolix , ≥98% , 737789-87-6
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB624.80 | In Stock |
|
| 5mg | RMB1071.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9)) |
| Density | 1.442±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:20.0(Max Conc. mg/mL);32.1(Max Conc. mM) Ethanol:1.0(Max Conc. mg/mL);1.6(Max Conc. mM) |
| form | A crystalline solid |
| pka | 13.17±0.70(Predicted) |
| color | White to off-white |
| InChIKey | AOMXMOCNKJTRQP-UHFFFAOYSA-N |
| SMILES | N(C1=CC=C(C2SC3=C(C=2CN(C)C)C(=O)N(C2=NN=C(OC)C=C2)C(=O)N3CC2=C(F)C=CC=C2F)C=C1)C(NOC)=O |
Description and Uses
Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. It possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.
Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Warning |
| Hazard statements | H361-H371 |
| Precautionary statements | P201-P202-P281-P308+P313-P405-P501-P260-P264-P270-P309+P311-P405-P501 |
